Serum Chromogranin A is a Predictor for Liver Metastatic Tumor Burden and Therapeutic Response in Advanced Non-Functional Pancreatic Neuroendocrine Tumors Abstract #809

Introduction: The relationship between CgA level and liver metastatic (LM) tumor burden as well as therapeutic response is not well-established.
Aim(s): To investigate significance of CgA in the prediction of LM tumor burden and treatment response in advanced NF-PNETs.
Materials and methods: Sixty-four pts were enrolled from Dec 2011 to Sep 2013. Measurement of serum CgA was performed with ELISA Kit (CisBio) from fasted pts. The decreased/elevated CgA was defined as <50%/>50% level from baseline. We computed LM tumor burden from CT/MRI scan with less than 5mm thin slices including most amount of detectable metastases by a semiquantitative three-dimensional reconstruction approach. Change in LM tumor burden was defined as response or progression using RECIST criteria.
Conference: 11th Annual ENETS Conference (2014)
Category: Biomarkers
Presenting Author: M.D. Xu Han
Keywords: CgA NF-PNETs LM

To read results and conclusion, please login ...

Further abstracts you may be interested in

#808 Characteristics and Determinants of Long-Term Outcome for Resectable Sporadic Non-Functional Pancreatic Neuroendocrine Tumors (NF-PNETs): Updated 16-year Experience from Two Large Chinese Centers
Introduction: Non-functional pancreatic neuroendocrine tumors (NF-PNETs) are increasingly recognized with unique biology.
Conference: 11th Annual ENETS Conference (2014)
Category: Surgical treatment
Presenting Author: M.D. Xu Han
Authors: Jin G, Han X, Jin D, Hu X, ...
Keywords: NF-PNETs
#1597 The Diagnostic and Prognostic Value of Plasma CgA in Nonfunctional Pancreatic Neuroendocrine Neoplasms
Introduction: Controversies still remain on the diagnostic and prognostic value of CgA.
Conference: 14th Annual ENETS conference (2017)
Category: Biomarkers
Presenting Author: Yang Lv
Authors: Lv Y, Han X, Mao W, Zhou J, ...
#1599 The Value of Plasma CgA Combined with NSE Performed As the Real-Time Monitor of Clinical Characteristics in Gastroenteropancreatic Neuroendocrine Neoplasms after the Resection of Primary Lesions
Introduction: Controversies still remain on the clinical value of CgA and NSE.
Conference: 14th Annual ENETS conference (2017)
Category: Biomarkers
Presenting Author: Yang Lv
Authors: Lv Y, Han X, Mao W, Zhou J, ...
Keywords: cga, nse, nf-gep-nens
#1360 Development and Validation of Nomogram in Predicting Individualized Postoperative Survival for Nonfunctional Pancreatic Neuroendocrine Tumors: A Multicenter Retrospective Study
Introduction: NA
Conference: 13th Annual ENETS conference (2016)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Xu Han
Authors: Han X, Ma H, Feng J, Xu X, ...
#1398 Surgical Management of Nonfunctioning Pancreatic Neuroendocrine Tumors 2 cm or Less in Size: Results from a Multi-institutional Clinical Analysis in China
Introduction: There is a paucity of evidence regarding surgical management and survival in nonfunctioning PNETs 2cm or less.
Conference: 13th Annual ENETS conference (2016)
Category: Surgical treatment
Presenting Author: Meng Ji
Authors: Ji M, Jin K, Zhang Y, ...
Close
Notice
Important Notice:

In preparation of the upcoming 16th Annual ENETS Conference, 6 to 8 March 2019 in Barcelona, Spain, we have discovered in the world wide web at least one professional entity suggestive of possessing an ENETS mandate for conference registrations. Therefore, we must inform you that 100% of all conference participants are registered through ENETS official website www.enets.org and http://enetsconference.org/. There are no further options to validly register for Barcelona 2019 (or for any other ENETS event).

Please stay away from fraudulent scams abusing the ENETS acronym to register – and charge you above official ENETS conference fees! Such entities, against whom ENETS presses criminal charges, are neither authorized, nor commissioned nor instructed by ENETS to make such representations.